Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1-Reference-Cited by-同舟云学术

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Published:2015-06 Issue: Volume:15 Page:S167-S169
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Choi Michael Y.,Widhopf George F.,Wu Christina C.N.,Cui Bing,Lao Fitzgerald,Sadarangani Anil,Cavagnaro Joy,Prussak Charles,Carson Dennis A.,Jamieson Catriona,Kipps Thomas J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction;Green;Cold Spring Harb Perspect Biol,2014

2. A novel family of cell surface receptors with tyrosine kinase-like domain;Masiakowski;J Biol Chem,1992

3. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans;Yoda;J Recept Signal Transduct Res,2003

4. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia;Broome;Leuk Res,2011

5. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells;Klein;J Exp Med,2001

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel humanized monoclonal antibodies against ROR1 for cancer therapy;Molecular Cancer;2024-08-13

2. Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy;Journal of Leukocyte Biology;2024-07-08

3. miRNA Biology in Chronic Lymphocytic Leukemia;Seminars in Hematology;2024-06

4. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17

5. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer;Breast Cancer Research;2024-02-26